点击蓝字，关注我们 贝达药业三度冲击港股IPO：资金链承压、研发缩水与产品困局 | 年份/期间 | 营业收入 | 同比增速 | 归母净利润 | 同比增速 | 扣非归母净利润 | 同比增速 | | --- | --- | --- | --- | --- | --- | --- | | 2021年 | 22.46 | l | 3.83 | l | | | | 2022年 | 23.77 | 5.84% | 1.45 | -62.14% | l | - | | 2023年 | 24.56 | 3.34% | 3.48 | 139.99% | - | l | | 2024年 | 28.92 | 17.79% | 4.03 | 15.80% | l | - | | 2025年上半年 | 17.31 | 15.37% | 1.40 | -37.53% | l | -11.97% | | 2025年Q2 | 8.14 | 6.39% | 0.40 | -68.36% | - | l | | 年份/期间 | 货币资金余额 | 流动资产 | 流动负债 | 经营活动现金流净额 | 同比增速 | | --- | --- | --- ...

Core Viewpoint - The company has a total of eight products in its sales pipeline and aims to leverage its successful commercialization experience in oncology to enhance market coverage through differentiated clinical value and efficient promotion strategies [2]. Group 1: Product Information - The company currently has several products for sale, including 凯美纳, 贝美纳, 贝安汀, 赛美纳, 伏美纳, and 康美纳, which was approved for sale on June 30. Additionally, 安瑞泽 started sales in July, and a plant-derived recombinant human albumin injection (水稻) named 奥福民 was also approved in July [2]. Group 2: Sales Performance and Strategy - The company is addressing questions regarding its sales performance compared to industry peers, specifically mentioning that its revenue, gross profit, and net profit metrics are currently lower than those of艾力斯. The company emphasizes the importance of innovation and adaptability in response to new challenges in the industry [2].